Spectrum separation resolves partial-volume effect of MRSI as demonstrated on brain tumor scans

Yuzhuo Su, Sunitha B. Thakur, Sasan Karimi, Shuyan Du, Paul Sajda, Wei Huang, Lucas C. Parra

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Magnetic resonance spectroscopic imaging (MRSI) is currently used clinically in conjunction with anatomical MRI to assess the presence and extent of brain tumors and to evaluate treatment response. Unfortunately, the clinical utility of MRSI is limited by significant variability of in vivo spectra. Spectral profiles show increased variability because of partial coverage of large voxel volumes, infiltration of normal brain tissue by tumors, innate tumor heterogeneity, and measurement noise. We address these problems directly by quantifying the abundance (i.e. volume fraction) within a voxel for each tissue type instead of the conventional estimation of metabolite concentrations from spectral resonance peaks. This 'spectrum separation' method uses the non-negative matrix factorization algorithm, which simultaneously decomposes the observed spectra of multiple voxels into abundance distributions and constituent spectra. The accuracy of the estimated abundances is validated on phantom data. The presented results on 20 clinical cases of brain tumor show reduced cross-subject variability. This is reflected in improved discrimination between high-grade and low-grade gliomas, which demonstrates the physiological relevance of the extracted spectra. These results show that the proposed spectral analysis method can improve the effectiveness of MRSI as a diagnostic tool.

Original languageEnglish (US)
Pages (from-to)1030-1042
Number of pages13
JournalNMR in Biomedicine
Volume21
Issue number10
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Magnetic resonance
Brain Neoplasms
Tumors
Brain
Magnetic Resonance Imaging
Imaging techniques
Tissue
Glioma
Noise
Metabolites
Factorization
Infiltration
Magnetic resonance imaging
Spectrum analysis
Volume fraction
Neoplasms

Keywords

  • Brain tumor
  • Magnetic resonance spectroscopic imaging (MRSI)
  • Non-negative matrix factorization (NMF)
  • Tumor grade classification

ASJC Scopus subject areas

  • Spectroscopy
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Spectrum separation resolves partial-volume effect of MRSI as demonstrated on brain tumor scans. / Su, Yuzhuo; Thakur, Sunitha B.; Karimi, Sasan; Du, Shuyan; Sajda, Paul; Huang, Wei; Parra, Lucas C.

In: NMR in Biomedicine, Vol. 21, No. 10, 12.2008, p. 1030-1042.

Research output: Contribution to journalArticle

Su, Yuzhuo ; Thakur, Sunitha B. ; Karimi, Sasan ; Du, Shuyan ; Sajda, Paul ; Huang, Wei ; Parra, Lucas C. / Spectrum separation resolves partial-volume effect of MRSI as demonstrated on brain tumor scans. In: NMR in Biomedicine. 2008 ; Vol. 21, No. 10. pp. 1030-1042.
@article{26a05f7447c247bc9e70bdf250292d92,
title = "Spectrum separation resolves partial-volume effect of MRSI as demonstrated on brain tumor scans",
abstract = "Magnetic resonance spectroscopic imaging (MRSI) is currently used clinically in conjunction with anatomical MRI to assess the presence and extent of brain tumors and to evaluate treatment response. Unfortunately, the clinical utility of MRSI is limited by significant variability of in vivo spectra. Spectral profiles show increased variability because of partial coverage of large voxel volumes, infiltration of normal brain tissue by tumors, innate tumor heterogeneity, and measurement noise. We address these problems directly by quantifying the abundance (i.e. volume fraction) within a voxel for each tissue type instead of the conventional estimation of metabolite concentrations from spectral resonance peaks. This 'spectrum separation' method uses the non-negative matrix factorization algorithm, which simultaneously decomposes the observed spectra of multiple voxels into abundance distributions and constituent spectra. The accuracy of the estimated abundances is validated on phantom data. The presented results on 20 clinical cases of brain tumor show reduced cross-subject variability. This is reflected in improved discrimination between high-grade and low-grade gliomas, which demonstrates the physiological relevance of the extracted spectra. These results show that the proposed spectral analysis method can improve the effectiveness of MRSI as a diagnostic tool.",
keywords = "Brain tumor, Magnetic resonance spectroscopic imaging (MRSI), Non-negative matrix factorization (NMF), Tumor grade classification",
author = "Yuzhuo Su and Thakur, {Sunitha B.} and Sasan Karimi and Shuyan Du and Paul Sajda and Wei Huang and Parra, {Lucas C.}",
year = "2008",
month = "12",
doi = "10.1002/nbm.1271",
language = "English (US)",
volume = "21",
pages = "1030--1042",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Spectrum separation resolves partial-volume effect of MRSI as demonstrated on brain tumor scans

AU - Su, Yuzhuo

AU - Thakur, Sunitha B.

AU - Karimi, Sasan

AU - Du, Shuyan

AU - Sajda, Paul

AU - Huang, Wei

AU - Parra, Lucas C.

PY - 2008/12

Y1 - 2008/12

N2 - Magnetic resonance spectroscopic imaging (MRSI) is currently used clinically in conjunction with anatomical MRI to assess the presence and extent of brain tumors and to evaluate treatment response. Unfortunately, the clinical utility of MRSI is limited by significant variability of in vivo spectra. Spectral profiles show increased variability because of partial coverage of large voxel volumes, infiltration of normal brain tissue by tumors, innate tumor heterogeneity, and measurement noise. We address these problems directly by quantifying the abundance (i.e. volume fraction) within a voxel for each tissue type instead of the conventional estimation of metabolite concentrations from spectral resonance peaks. This 'spectrum separation' method uses the non-negative matrix factorization algorithm, which simultaneously decomposes the observed spectra of multiple voxels into abundance distributions and constituent spectra. The accuracy of the estimated abundances is validated on phantom data. The presented results on 20 clinical cases of brain tumor show reduced cross-subject variability. This is reflected in improved discrimination between high-grade and low-grade gliomas, which demonstrates the physiological relevance of the extracted spectra. These results show that the proposed spectral analysis method can improve the effectiveness of MRSI as a diagnostic tool.

AB - Magnetic resonance spectroscopic imaging (MRSI) is currently used clinically in conjunction with anatomical MRI to assess the presence and extent of brain tumors and to evaluate treatment response. Unfortunately, the clinical utility of MRSI is limited by significant variability of in vivo spectra. Spectral profiles show increased variability because of partial coverage of large voxel volumes, infiltration of normal brain tissue by tumors, innate tumor heterogeneity, and measurement noise. We address these problems directly by quantifying the abundance (i.e. volume fraction) within a voxel for each tissue type instead of the conventional estimation of metabolite concentrations from spectral resonance peaks. This 'spectrum separation' method uses the non-negative matrix factorization algorithm, which simultaneously decomposes the observed spectra of multiple voxels into abundance distributions and constituent spectra. The accuracy of the estimated abundances is validated on phantom data. The presented results on 20 clinical cases of brain tumor show reduced cross-subject variability. This is reflected in improved discrimination between high-grade and low-grade gliomas, which demonstrates the physiological relevance of the extracted spectra. These results show that the proposed spectral analysis method can improve the effectiveness of MRSI as a diagnostic tool.

KW - Brain tumor

KW - Magnetic resonance spectroscopic imaging (MRSI)

KW - Non-negative matrix factorization (NMF)

KW - Tumor grade classification

UR - http://www.scopus.com/inward/record.url?scp=59849092352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849092352&partnerID=8YFLogxK

U2 - 10.1002/nbm.1271

DO - 10.1002/nbm.1271

M3 - Article

VL - 21

SP - 1030

EP - 1042

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 10

ER -